New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium at 8 a.m. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.
Starting soon: SURPASS clinical trials may lead to the next chapter in incretin-based therapies
